Alibaba Health Information Technology Limited (ALBBY) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALBBY, $ (piyasa değeri 0) fiyatla Healthcare işi olan Alibaba Health Information Technology Limited'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 46/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 17 Mar 2026Alibaba Health Information Technology Limited (ALBBY) Sağlık ve Boru Hattı Genel Bakışı
Alibaba Health Information Technology Limited is a leading healthcare company in China, providing pharmaceutical e-commerce, direct sales, and digital healthcare services. The company leverages its parent company's technology and platform to offer a comprehensive suite of healthcare solutions, including online pharmacies, medical consultations, and health management tools.
Yatırım Tezi
Alibaba Health presents a compelling investment case due to its strategic positioning within China's rapidly expanding digital healthcare market. The company's integration with Alibaba's vast ecosystem provides a significant competitive advantage, driving user acquisition and engagement. With a P/E ratio of 31.49 and a profit margin of 5.8%, the company demonstrates profitability and growth potential. Key growth catalysts include the increasing adoption of online healthcare services in China and the expansion of Alibaba Health's service offerings. However, investors should be aware of regulatory risks and competition within the Chinese healthcare market. The company's high beta of 1.72 indicates higher volatility compared to the market.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $12.50 billion, reflecting substantial investor confidence in the company's market position.
- P/E ratio of 31.49, indicating a premium valuation based on earnings, suggesting strong growth expectations.
- Profit margin of 5.8%, demonstrating the company's ability to generate profit from its revenue streams.
- Gross margin of 24.5%, reflecting the efficiency of its operations in managing the cost of goods sold.
- Beta of 1.72, indicating higher volatility compared to the market, which may appeal to risk-tolerant investors seeking higher returns.
Rakipler & Benzerleri
Güçlü Yönler
- Strong brand recognition and reputation.
- Integration with Alibaba's ecosystem.
- Extensive online and offline network.
- Proprietary technology and data analytics.
Zayıflıklar
- Reliance on Alibaba's ecosystem.
- Exposure to regulatory risks in China.
- Competition from other online healthcare platforms.
- Relatively low profit margin.
Katalizörler
- Ongoing: Expansion of online pharmacy business driven by increasing internet penetration in China.
- Ongoing: Development of digital healthcare services, including online consultations and remote monitoring.
- Upcoming: Potential regulatory changes in China that could favor online healthcare platforms.
- Ongoing: Strategic partnerships with hospitals and clinics to integrate online and offline services.
Riskler
- Potential: Changes in government regulations regarding online pharmacies and healthcare services.
- Ongoing: Increased competition from other online healthcare platforms and traditional pharmacies.
- Potential: Data security and privacy concerns related to the collection and use of patient data.
- Potential: Economic slowdown in China that could impact consumer spending on healthcare products and services.
Büyüme Fırsatları
- Expansion of Online Pharmacy Business: The increasing adoption of online pharmacies in China presents a significant growth opportunity for Alibaba Health. As consumers become more comfortable purchasing prescription drugs and healthcare products online, Alibaba Health can leverage its e-commerce platform and logistics network to capture a larger share of the market. The Chinese online pharmacy market is projected to reach $50 billion by 2028, offering substantial growth potential.
- Development of Digital Healthcare Services: Alibaba Health can further expand its digital healthcare services, such as online consultations, remote monitoring, and chronic disease management. These services address the growing demand for convenient and accessible healthcare solutions. The digital healthcare market in China is expected to reach $200 billion by 2027, driven by government support and increasing consumer adoption.
- Strategic Partnerships with Hospitals and Clinics: Collaborating with hospitals and clinics to integrate online and offline healthcare services can enhance Alibaba Health's service offerings and expand its reach. These partnerships can enable the company to provide a more comprehensive and integrated healthcare experience for patients. The market for integrated healthcare solutions is growing rapidly, driven by the need for more efficient and coordinated care.
- Leveraging Artificial Intelligence and Big Data: Utilizing AI and big data analytics to personalize healthcare recommendations, improve diagnosis accuracy, and optimize treatment plans can enhance the value of Alibaba Health's services. These technologies can also help the company identify emerging health trends and develop innovative solutions. The AI in healthcare market is projected to reach $34 billion by 2025, offering significant opportunities for innovation and growth.
- Geographic Expansion within China: Expanding its presence in Tier 2 and Tier 3 cities in China can enable Alibaba Health to reach a wider customer base and tap into underserved markets. These cities are experiencing rapid economic growth and increasing demand for healthcare services. The healthcare market in Tier 2 and Tier 3 cities is expected to grow at a faster rate than in Tier 1 cities, presenting a significant growth opportunity.
Fırsatlar
- Expansion of online pharmacy business.
- Development of digital healthcare services.
- Strategic partnerships with hospitals and clinics.
- Leveraging AI and big data analytics.
Tehditler
- Changes in government regulations.
- Increased competition from domestic and international players.
- Data security and privacy concerns.
- Economic slowdown in China.
Rekabet Avantajları
- Strong brand recognition and reputation in the Chinese healthcare market.
- Integration with Alibaba's vast ecosystem of users and technology infrastructure.
- Extensive network of online and offline pharmacies.
- Proprietary technology and data analytics capabilities.
ALBBY Hakkında
Alibaba Health Information Technology Limited, formerly known as CITIC 21CN Company Limited, rebranded in September 2014 to align with its parent company, Alibaba Group. The company operates as an investment holding entity with a focus on pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services. Its primary market is Mainland China and Hong Kong. Alibaba Health offers a wide array of products, including prescription drugs, over-the-counter medications, nutritional supplements, and medical devices, accessible through its online stores on Tmall.com and its network of offline pharmacy outlets, catering to both business-to-customer (B2C) and business-to-business (B2B) segments. The company's e-commerce platform extends its offerings to include health food, sexual health products, contact lenses, and medical and healthcare services. Alibaba Health provides medical services such as checkups, testing, consultations, and vaccinations through various digital channels like Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. Furthermore, it engages in tracking services, network hospital operations, and the provision of internet and technical services related to healthcare, including the operation of internet hospitals and asset management.
Ne Yaparlar
- Operates online pharmacies selling prescription and over-the-counter drugs.
- Provides medical and healthcare services through digital channels.
- Offers health-related products, including nutritional supplements and medical devices.
- Manages an e-commerce platform for healthcare products and services.
- Engages in pharmaceutical direct sales to businesses and consumers.
- Provides tracking services for pharmaceutical products.
- Operates internet hospitals and provides related technical services.
İş Modeli
- Generates revenue through the sale of pharmaceutical products and healthcare services on its online platforms.
- Earns commissions from third-party vendors selling products on its e-commerce platform.
- Provides subscription-based healthcare services to consumers and businesses.
- Offers advertising and marketing services to healthcare companies.
Sektör Bağlamı
Alibaba Health operates within the rapidly growing digital healthcare market in China. This market is driven by increasing internet penetration, rising healthcare costs, and government support for online healthcare initiatives. The competitive landscape includes both domestic players and international companies seeking to capitalize on the growing demand for digital healthcare solutions. Alibaba Health benefits from its affiliation with Alibaba Group, which provides a vast ecosystem of users and technology infrastructure. The company competes with other online pharmacies and healthcare platforms, such as JD Health and Ping An Good Doctor.
Kilit Müşteriler
- Individual consumers seeking pharmaceutical products and healthcare services.
- Hospitals and clinics purchasing pharmaceutical products and healthcare solutions.
- Businesses offering healthcare benefits to their employees.
- Healthcare companies seeking to market their products and services.
Finansallar
Grafik & Bilgi
Alibaba Health Information Technology Limited (ALBBY) hisse senedi fiyatı: Price data unavailable
Son Haberler
ALBBY için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
ALBBY için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
ALBBY için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, ALBBY'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Difan Shen
CEO
Difan Shen is the CEO of Alibaba Health Information Technology Limited. Information regarding his detailed career history, education, and previous roles is not available in the provided context. However, as CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the rapidly evolving digital healthcare market in China.
Sicil: Specific achievements and milestones under Difan Shen's leadership are not detailed in the provided context. As CEO, he is responsible for driving the company's growth and profitability, expanding its service offerings, and navigating the complex regulatory landscape in China.
Alibaba Health Information Technology Limited ADR Bilgileri Sponsorsuz
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ALBBY is an ADR that allows U.S. investors to invest in Alibaba Health Information Technology Limited without directly purchasing shares on the Hong Kong Stock Exchange. The ADR represents a specific number of underlying ALBB shares.
- Ana Piyasa Sembolü: Hong Kong Stock Exchange (ALBB), Hong Kong
- ADR Seviyesi: 1
- ADR Oranı: 1:1
- Ana Piyasa Sembolü: ALBB
ALBBY OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited or no financial disclosure requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or suspension of trading.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Obtain and review the company's financial statements, if available.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk factors.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Affiliation with Alibaba Group.
- Established presence in the Chinese healthcare market.
- Operation of online and offline pharmacies.
- Provision of digital healthcare services.
ALBBY Healthcare Hisse Senedi SSS
ALBBY için değerlendirilmesi gereken temel faktörler nelerdir?
Alibaba Health Information Technology Limited (ALBBY) şu anda yapay zeka skoru 46/100, düşük puanı gösteriyor. Temel güçlü yan: Strong brand recognition and reputation.. İzlenmesi gereken birincil risk: Potential: Changes in government regulations regarding online pharmacies and healthcare services.. Bu bir finansal tavsiye değildir.
ALBBY MoonshotScore'u nedir?
ALBBY şu anda MoonshotScore'da 46/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
ALBBY verileri ne sıklıkla güncellenir?
ALBBY fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler ALBBY hakkında ne diyor?
ALBBY için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
ALBBY'a yatırım yapmanın riskleri nelerdir?
ALBBY için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Changes in government regulations regarding online pharmacies and healthcare services.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
ALBBY'ın P/E oranı nedir?
ALBBY için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ALBBY'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
ALBBY aşırı değerli mi, yoksa düşük değerli mi?
Alibaba Health Information Technology Limited (ALBBY)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
ALBBY'ın temettü verimi nedir?
Alibaba Health Information Technology Limited (ALBBY) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.